Kane Biotech Inc.
KNBIF
$0.0643
-$0.002-3.02%
| Weiss Ratings | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | C | |||
| Rating Factors | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Good | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.35 | |||
| Price History | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.02% | |||
| 30-Day Total Return | -19.63% | |||
| 60-Day Total Return | -19.63% | |||
| 90-Day Total Return | -33.71% | |||
| Year to Date Total Return | -16.49% | |||
| 1-Year Total Return | -12.64% | |||
| 2-Year Total Return | -13.46% | |||
| 3-Year Total Return | -33.98% | |||
| 5-Year Total Return | -53.64% | |||
| 52-Week High % Change | -47.63% | |||
| 52-Week Low % Change | 3.54% | |||
| Price | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.12 | |||
| 52-Week Low Price | $0.06 | |||
| 52-Week Low Price (Date) | Feb 25, 2025 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.22M | |||
| Enterprise Value | 11.43M | |||
| Price/Earnings (TTM) | 2.41 | |||
| Earnings Per Share (TTM) | 0.03 | |||
| Earnings Per Share Growth | -196.39% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.85 | |||
| Price/Book (Q) | -17.38 | |||
| Enterprise Value/Revenue (TTM) | 7.74 | |||
| Price | $0.06 | |||
| Enterprise Value/EBITDA (TTM) | -3.82 | |||
| Enterprise Value/EBIT | -3.76 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 133.79M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 204-453-1301 | |||
| Address | 100 Innovation Drive Winnipeg, MB R3T 6G2 | |||
| Website | kanebiotech.com | |||
| Country | Canada | |||
| Year Founded | 2001 | |||
| Profitability | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -205.79% | |||
| Profit Margin | 278.48% | |||
| Management Effectiveness | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -51.70% | |||
| Return on Equity | -- | |||
| Income Statement | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.47M | |||
| Total Revenue (TTM) | 1.47M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 727.40K | |||
| EBITDA (TTM) | -2.99M | |||
| EBIT (TTM) | -3.03M | |||
| Net Income (TTM) | 4.10M | |||
| Net Income Avl. to Common (TTM) | 4.10M | |||
| Total Revenue Growth (Q YOY) | 4,579.10% | |||
| Earnings Growth (Q YOY) | 46.35% | |||
| EPS Diluted (TTM) | 0.03 | |||
| EPS Diluted Growth (Q YOY) | 15.85% | |||
| Balance Sheet | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 403.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 1.64M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -509.70K | |||
| Current Ratio (Q) | 0.802 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 2.89M | |||
| Total Current Liabilities (Q) | 2.04M | |||
| Total Debt (Q) | 1.70M | |||
| Total Liabilities (Q) | 3.40M | |||
| Total Common Equity (Q) | -509.70K | |||
| Cash Flow | KNBIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 6.59M | |||
| Cash from Financing (TTM) | -4.11M | |||
| Net Change in Cash (TTM) | -1.63M | |||
| Levered Free Cash Flow (TTM) | -1.68M | |||
| Cash from Operations (TTM) | -4.11M | |||
